Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis

Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis

<p><strong>Objective:</strong> Assess pooled safety results through the end of the Phase 2/3 studies of guselkumab (≤2 years) in tumor necrosis factor-α inhibitor (TNFi) -naïve and -experienced patients with psoriatic arthritis (PsA).</p> <p><strong>Methods:<...

Full description

Bibliographic Details
Main Authors: Rahman, P, Boehncke, W-H, Mease, PJ, Gottlieb, AB, McInnes, IB, Shawi, M, Wang, Y, Sheng, S, Kollmeier, AP, Theander, E, Yu, J, Leibowitz, E, Marrache, AM, Coates, LC
Format: Journal article
Language:English
Published: Journal of Rheumatology 2023

Similar Items